

Sarborg Develops and Curates “Sarborg 1,600” Gold Standard Disease Signature Database

WILMINGTON, De -- December 15, 2025 -- Sarborg Limited (“Sarborg” or the “Company”), today announced the curation and development of its proprietary “Sarborg 1,600,” a gold standard database of approximately 1,600 structured disease signatures designed specifically for integration with the Company’s AI Signature Agent.

The Sarborg 1,600 represents a comprehensive and systematically curated library of disease-level biological signatures spanning a broad range of therapeutic areas. These include, but are not limited to, oncology, immunology, neurology, metabolic disorders, infectious diseases and rare conditions.

Each disease signature has been standardised into a structured format suitable for direct computational pairing against drug signatures within the Company’s Signature Agent framework. By encoding gene expression patterns, pathway-level dynamics and associated biological markers into consistent signature architectures, Sarborg has established a scalable and internally coherent disease reference layer.

The Sarborg 1,600 enables rapid, real-time comparative analysis between drug and disease signatures. When a drug signature is input into the Signature Agent, it can be systematically paired against the full disease library, generating ranked outputs based on gene-level alignment, pathway correlation and overall biological concordance.

This architecture allows the Company to:

- Rapidly screen drug signatures across a wide spectrum of disease indications
- Generate prioritised indication rankings within minutes
- Provide structured scientific outputs suitable for research and commercial evaluation
- Maintain consistency and reproducibility across analyses

The breadth of therapeutic areas represented within the Sarborg 1,600 provides a robust validation framework for identifying potential repurposing or novel indication opportunities. By screening against a diverse and comprehensive disease universe, the Signature Agent can surface high-signal alignments that may not be immediately apparent through conventional research methodologies.

The Sarborg 1,600 forms a core component of Sarborg’s signature intelligence infrastructure and will serve as a foundational dataset for both internal strategic development and prospective client engagements within the pharmaceutical sector.

Sarborg will continue to expand, refine and standardise its signature libraries as part of its broader objective to establish signatures as a universal data language for scientific and commercial opportunity identification.

About Sarborg Limited

Sarborg is an agentic AI signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures, Sarborg’s agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:

info@sarborg.com

www.sarborg.com